• Explore /
  • Poster
  • / Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study.

Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study.

Abstract Poster

Authors

Xiaojia Wang, III

Xiaojia Wang

Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, China

Xiaojia Wang , Keun Seok Lee , Xiaohua Zeng , Tao Sun , Young-Hyuck Im , Huiping Li , Kun Wang , Huiyan Li , Ping Zhou , Yuanyuan Bao , Zefei Jiang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT04276493

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 1044)

DOI

10.1200/JCO.2023.41.16_suppl.1044

Abstract #

1044

Poster Bd #

265

Abstract Disclosures

Similar Posters

First Author: Xiaojia Wang

First Author: Keun-Seok Lee

First Author: Keun Wook Lee

First Author: Do-Youn Oh